176 related articles for article (PubMed ID: 29477409)
1. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
[TBL] [Abstract][Full Text] [Related]
2.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
3. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
[TBL] [Abstract][Full Text] [Related]
4. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
7. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages.
Lee GT; Kwon SJ; Kim J; Kwon YS; Lee N; Hong JH; Jamieson C; Kim WJ; Kim IY
Br J Cancer; 2018 Mar; 118(5):670-678. PubMed ID: 29381686
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
10. The transcription factor SPDEF suppresses prostate tumor metastasis.
Steffan JJ; Koul S; Meacham RB; Koul HK
J Biol Chem; 2012 Aug; 287(35):29968-78. PubMed ID: 22761428
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
[TBL] [Abstract][Full Text] [Related]
12. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
14. Regulation of SPDEF expression by DNA methylation in advanced prostate cancer.
Vatanmakanian M; Steffan JJ; Koul S; Ochoa AC; Chaturvedi LS; Koul HK
Front Endocrinol (Lausanne); 2023; 14():1156120. PubMed ID: 37900138
[TBL] [Abstract][Full Text] [Related]
15. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
16. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
Cheng XH; Black M; Ustiyan V; Le T; Fulford L; Sridharan A; Medvedovic M; Kalinichenko VV; Whitsett JA; Kalin TV
PLoS Genet; 2014 Sep; 10(9):e1004656. PubMed ID: 25254494
[TBL] [Abstract][Full Text] [Related]
17. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
[TBL] [Abstract][Full Text] [Related]
18. Indole-3-carbinol and 3',3'-diindolylmethane modulate androgen's effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells.
Kim EK; Kim YS; Milner JA; Wang TT
Cancer Prev Res (Phila); 2013 Jun; 6(6):519-29. PubMed ID: 23585426
[TBL] [Abstract][Full Text] [Related]
19. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
[TBL] [Abstract][Full Text] [Related]
20. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.
Sun T; Wang X; He HH; Sweeney CJ; Liu SX; Brown M; Balk S; Lee GS; Kantoff PW
Oncogene; 2014 May; 33(21):2790-800. PubMed ID: 23770851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
